Sunitinib and Reversible Posterior Leukoencephalopathy Syndrome: the usual suspect but not always the culprit. A case report.

[1] Cancer Genome Atlas Research, N., et al., Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med, 2016. 374(2): p. 135–45. Cancer Genome Atlas Research, N., et al., Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma N Engl J Med 2016 374 2 135 45 Search in Google Scholar

[2] Shuch B., et al., Current treatment Landscape of Advanced Papillary Renal Cell Cancer. Journal of Clinical Oncology, Vol 35, No26, (Sept 10), 2017: pp 2981–2983 ShuchB. Current treatment Landscape of Advanced Papillary Renal Cell Cancer Journal of Clinical Oncology 35 26 Sept 10 2017 2981 2983 Search in Google Scholar

[3] Schmid, T.A. and M.E. Gore, Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol, 2016. 8(6): p. 348–371. SchmidT.A. GoreM.E. Sunitinib in the treatment of metastatic renal cell carcinoma Ther Adv Urol 2016 8 6 348 371 Search in Google Scholar

[4] Fukui, S., et al, Reversible Posteior Leukoencephalopathy Syndrome Developing After restart of Sunitinib Therapy for Metastatic Renal Cell Carcinoma. Case Reports in Medicine, Vol 2016, Article ID 6852951 FukuiS. Reversible Posteior Leukoencephalopathy Syndrome Developing After restart of Sunitinib Therapy for Metastatic Renal Cell Carcinoma Case Reports in Medicine 2016 Article ID 6852951 Search in Google Scholar

[5] Stenman, M., et al, Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres. Acta Oncologica, 58:3,306–312, DOI: 10.1080/0284186X.2018.1537505 StenmanM. Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres Acta Oncologica 58 3 306 312 10.1080/0284186X.2018.1537505 Open DOISearch in Google Scholar

[6] Khan, K.H. et al, Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature. Tumori, 2012. 98: e139–e142. KhanK.H. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature Tumori 2012 98 e139 e142 Search in Google Scholar

[7] Hinduja, A., Posterior Reversible Encephalopathy Syndrome: Clinical Features and Outcome. Front Neurol, 2020. 11: p. 71. HindujaA. Posterior Reversible Encephalopathy Syndrome: Clinical Features and Outcome Front Neurol 2020 11 71 Search in Google Scholar

[8] Gao, B., et al., Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years? J Neurol Neurosurg Psychiatry, 2018. 89(1): p. 14–20. GaoB. Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years? J Neurol Neurosurg Psychiatry 2018 89 1 14 20 Search in Google Scholar

[9] Kastrup, O., et al., Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns. J Neurol, 2012. 259(7): p. 1383–9. KastrupO. Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns J Neurol 2012 259 7 1383 9 Search in Google Scholar

[10] Fugate, J.E. and A.A. Rabinstein, Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol, 2015. 14(9): p. 914–925. FugateJ.E. RabinsteinA.A. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions Lancet Neurol 2015 14 9 914 925 Search in Google Scholar